Rob Davis (Merck)
May 19, 2021 05:38 AM EDTUpdated 11:01 AM
Bioregnum
Pharma

There’s a new team oc­cu­py­ing the ex­ec­u­tive suite at Mer­ck. And they’ve got a new game plan

Now that Rob Davis and his new­ly re­cruit­ed crew of C-suite ex­ecs are about to take full con­trol of Mer­ck, it’s time to up­date the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times